Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00782587 · ClinicalTrials.gov registry record · Phase 1

Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer

A Phase 1 study, sponsored by Halozyme Therapeutics.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target

NCT00782587: Completed Phase 1 study, sponsored by Halozyme Therapeutics.

NCT00782587 is a Phase 1 study that has completed, run by Halozyme Therapeutics. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00782587, a Phase 1 study, has completed, sponsored by Halozyme Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target

Study Summary

The purpose of this research study is to test the safety and tolerability of an experimental drug, Chemophase, a combination of recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20), and mitomycin (MMC) in the treatment of superficial bladder cancer when instilled intravesically immediately after TURBT (transurethral resection of bladder tumor).

Interventions

  • DRUG Chemophase

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2008-10
Est. Completion 2009-08
Phase Phase 1
Halozyme Therapeutics

31 total trials

What the finished NCT00782587 record still lists

NCT00782587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 1 intervention - of which Chemophase is the first listed.

NCT00782587 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00782587 about?

NCT00782587 is a clinical study titled "Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer". The purpose of this research study is to test the safety and tolerability of an experimental drug, Chemophase, a combination of recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20), and mitomycin (MMC) in the treatment of superficial bladder cancer when instil...

What is the current status of trial NCT00782587?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2008-10. Estimated completion is 2009-08.

What interventions are being tested in trial NCT00782587?

The interventions under investigation include: Chemophase (DRUG).

Who is sponsoring clinical trial NCT00782587?

This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00782587's enrollment target sits among peer trials

14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00782587, the US trial registry maintained by the National Library of Medicine. NCT00782587 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.